Sponsor: EMD Millipore
Data presented in this webinar illustrates the value of live cell analysis at the single-cell level to identify differences in expression levels across populations of cells. The cells remain intact for downstream analysis. Our experts also discuss the use of SmartFlare RNA detection probes for the direct quantification of circulating miRNAs with rapid processing of blood plasma/serum, which is done without the use of enzymes. Using circulating miRNAs with established roles in cancer and quality control, we can accurately detect these miRNAs in plasma using a microplate fluorometer within an hour after plasma preparation.
On-demand recording is available here.
It actually seems as if the
It actually seems as if the $1000 genome might offer an end-run path around ridiculous patents that cover naturally occurring aspects of our own physiology (which certainly we, as the end products of the genes in question, technically "own"... unless perhaps as a creationist one wishes to ascribe ownership to a deity). Patents are for the use of things for specific purposes, and those purposes are usually publically available in the form of the patent materials themselves. This means that a person should be able to pay to collect their own genomic sequence (agnostic to purpose), then "decode" it, in a biomedically relevant fashion, themselves by simply looking at the patents that describe observed correlations between genotype and phenotype. After all, you don't need a company to make an associative connection for you if the association is published and the data comes in a readable form (and certainly, a 4-letter alphabet makes for a pretty simple form of reading!).